[New developments in antifungal therapy: fluconazole, itraconazole, voriconazole, caspofungin]
until further notice
SourceNederlands Tijdschrift voor Geneeskunde, 148, 34, (2004), pp. 1679-1684
Article / Letter to editor
Display more detailsDisplay less details
Nederlands Tijdschrift voor Geneeskunde
SubjectEBP 3: Effective Primary Care and Public Health; UMCN 4.1: Microbial pathogenesis and host defense
The azole antifungal voriconazole and the echinocandin caspofungin have recently become available for the treatment of invasive mycoses. Fluconazole remains the drug of choice for candidemia, except for infections with one of the resistent species such as Candida krusei and some strains of Candida glabrata. In these cases, as well as in patients who cannot tolerate azoles in connection with side effects or drug interactions, caspofungin is an attractive alternative. Voriconazole has become the drug of choice for severe invasive aspergillosis. Itraconazole is a good alternative for milder and chronic forms of aspergillosis. The use of conventional amphotericin B will be limited by the availability of the new drugs. In view of their high costs, the lipid-bound forms of amphotericin B will usually be given only as salvage therapy in case of failure, in patients who are unable to tolerate either conventional amphotericin or one of the newer agents, and for the treatment of zygomycosis.
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.